Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALM-1 Phase 3 study of BLU-5937 in refractory chronic cough
NL-OMON56306Phase 3Recruiting
- Sponsor
- BELLUS Health Inc.
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of camlipixant in refractory chronic cough (RCC) and chronic idiopathic cough (CIC) (4 arms), sponsored by BELLUS Health Inc. Primary endpoints: 24-hour cough frequency at Week 12, Incidence of adverse events and serious adverse events up to Week 52 and 5 more. Started Aug 2023; status: recruiting.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)chronic idiopathic cough (CIC)
Beyond the preview
Go deeper on NL-OMON56306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56306.